Your browser doesn't support javascript.
loading
Tumor-derived interleukin-1α and leukemia inhibitory factor promote extramedullary hematopoiesis.
Barisas, Derek A G; Kabir, Ashraf Ul; Wu, Jun; Krchma, Karen; Kim, Minseo; Subramanian, Madhav; Zinselmeyer, Bernd H; Stewart, Colin L; Choi, Kyunghee.
Afiliação
  • Barisas DAG; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Kabir AU; Immunology Program, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Wu J; Medical Scientist Training Program, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Krchma K; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Kim M; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Subramanian M; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Zinselmeyer BH; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Stewart CL; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Choi K; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
PLoS Biol ; 21(5): e3001746, 2023 05.
Article em En | MEDLINE | ID: mdl-37134077
ABSTRACT
Extramedullary hematopoiesis (EMH) expands hematopoietic capacity outside of the bone marrow in response to inflammatory conditions, including infections and cancer. Because of its inducible nature, EMH offers a unique opportunity to study the interaction between hematopoietic stem and progenitor cells (HSPCs) and their niche. In cancer patients, the spleen frequently serves as an EMH organ and provides myeloid cells that may worsen pathology. Here, we examined the relationship between HSPCs and their splenic niche in EMH in a mouse breast cancer model. We identify tumor produced IL-1α and leukemia inhibitory factor (LIF) acting on splenic HSPCs and splenic niche cells, respectively. IL-1α induced TNFα expression in splenic HSPCs, which then activated splenic niche activity, while LIF induced proliferation of splenic niche cells. IL-1α and LIF display cooperative effects in activating EMH and are both up-regulated in some human cancers. Together, these data expand avenues for developing niche-directed therapies and further exploring EMH accompanying inflammatory pathologies like cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Leucemia / Tratamento Base de dados: MEDLINE Assunto principal: Hematopoese Extramedular / Doenças Hematológicas / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: PLoS Biol Assunto da revista: BIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Leucemia / Tratamento Base de dados: MEDLINE Assunto principal: Hematopoese Extramedular / Doenças Hematológicas / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: PLoS Biol Assunto da revista: BIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos